Articles

The Market Herald – Invex taps investors for $26.2m after positive Exenatide trials

Click to view the full article

Partners

partner-preview
partner-preview-2
Premier_Research_Logo
University_Hospitals_Birmingham_NHS_Foundation_Trust_logo
MDT_logo
Iowa

Contact Us

Address

c/- Automic Group
Level 5, 191 St Georges Terrace
Perth WA 6000

Phone

+61 402 493 727

ACN

632145334

Email

info@invextherapeutics.com

Twitter Youtube Linkedin-in

Subscribe to our updates

Copyright © 2025 Invex Therapeutics. All rights reserved. Disclaimer.

Created by Anomaly.​